Global Blood Therapeutics is a biopharmaceutical company that focuses on developing treatments for underserved patient communities. Founded in 2011, the company's main goal is to transform the treatment and care of sickle cell disease, a lifelong inherited blood disorder. GBT has achieved this goal by introducing the first FDA-approved treatment, Oxbryta, which directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. The company is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. GBT's drug discovery teams are currently working on new targets to develop the next generation of treatments for SCD.
Global Blood Therapeutics's ticker is GBT
The company's shares trade on the ASX stock exchange
They are based in Brisbane, Queensland
There are 501-1000 employees working at Global Blood Therapeutics
It is gbt.com
Global Blood Therapeutics is in the Technology sector
Global Blood Therapeutics is in the Information Technology Services industry
The following five companies are Global Blood Therapeutics's industry peers: